Each coated tablet contains: Rosuvastatin (as Rosuvastatin Calcium) 10 mg. Excipients q.s.

Therapeutic action
Lipid-lowering. Inhibitor of HMG-CoA reductase

Hyperlipidemia and mixed dyslipidemia
Rosuvastatin is indicated as adjuvant therapy to diet to reduce C – total, LDL-C, Apoẞ, non HDL-C and elevated triglycerides and to increase HDL-C in adult patients with primary Hyperlipidemia or Mixed Dyslipidemia. Agents for treating lipid alterations should be used in combination with a diet restricted in saturated fat and cholesterol, and when the response to diet and non-pharmacological interventions has been insufficient.
Pediatric patients 10 to 17 years of age with heterozygous Familial Hypercholesterolemia (HeFH):
Rosuvastatin is indicated as a dietary supplement to reduce total C, LDL-C, and Apoẞ levels in male and female adolescent who are at least 1 year after menarche, 10-17 years of age with heterozygous familial hypercholesterolemia if the following results are present after an appropriate diet test: LDL-C> 190 mg / dl or 160 mg / dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more of other CVD risk factors.
Rosuvastatin is indicated as a dietary adjuvant for the treatment of adult patients with hypertriglyceridemia.
Primary dysbetalipoproteinemia (Hyperlipoproteinemia type III):
Rosuvastatin is indicated as a dietary adjuvant for the treatment of patients with primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
Homozygous familial hypercholesterolemia:
Rosuvastatin is indicated as adjuvant therapy to other lipid lowering treatments (eg LDL apheresis) or only if such treatments are not available to reduce LDL-C, C-total and Apoẞ in adult patients with homozygous familial hypercholesterolemia.
Delay on the progression of atherosclerosis:
Rosuvastatin is indicated as an adjuvant to diet to delay the progression of atherosclerosis in adult patients as part of a treatment strategy to reduce total C and LDL-C at target levels.
Primary prevention of cardiovascular events:
In adult patients with increased risk of cardiovascular disease, Arteriosclerotic, based on the presence of markers of risk for cardiovascular disease with a level of CRP ≥ 2, age (≥ 50 years in men and) ≥ 60 years for women), high blood pressure, HDL-C, smoking or a family history of premature coronary heart disease. Rosuvastatin is indicated to reduce the risk of stroke, arterial revascularization procedures and myocardial infarction.

Blister box containing 30 coated tablets.


El material incluído en este sitio ha sido concebido exclusivamente para los profesionales de la salud con fines informativos, y destinado a orientar sobre el uso adecuado de los medicamentos.
Todos los textos referidos a nuestros productos de venta bajo prescripción médica se corresponden a los lineamientos aprobados por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).

Denver Farma le sugiere consultar siempre a un profesional de la salud ante cualquier duda sobre una condición médica particular.